VAERS reports by lot

GSK Varicella/Shingles lot XG52X: VAERS reports

33 VAERS reports list lot XG52X as a GSK Varicella/Shingles vaccine, received between 2020-04-28 and 2022-02-03. Data: VAERS public files through 31 December 2024 (site extract 2026-07-04).

Read this first. VAERS accepts reports from anyone, and a report does not establish that the vaccine caused the event. A lot's report count mostly reflects how many doses it contained, when it was used and who received it; no administered-dose counts are published for this lot, so counts are not rates and cannot rank lots against each other. Lot numbers in VAERS reports are typed by reporters and are sometimes wrong.
33
Reports
0%
Marked serious
0
With a death outcome
14
Months with reports

Symptom categories in these reports

A report can mention several categories, so the counts add up to more than the number of reports.

CategoryCount%
General / Systemic (non-local)2722%
Neurological2016%
Musculoskeletal2016%
Injection-site / Local reaction2016%
Dermatological (non-injection-site)1512%
Gastrointestinal119%
Allergic / Anaphylactic65%
Cardiac / Cardiovascular43%
Respiratory22%

Where reports came from

U.S. state of the reporter, where given (top 12).

Pennsylvania7
Ohio5
North Carolina4
Florida4
Michigan3
South Carolina2
Hawaii2
Maryland1
Massachusetts1
New Jersey1
Minnesota1
Virginia1

Reports by month received

2020-041
2020-073
2020-092
2020-102
2020-111
2020-128
2021-014
2021-023
2021-031
2021-043
2021-062
2021-071
2021-091
2022-021

Products recorded with this lot

Manufacturer and product as reported in VAERS. Reports listing the lot under more than one product are counted once.

Related

Source: VAERS public data (CDC/FDA), grouped by manufacturer and lot by the Open Source Medicine Foundation; extract 2026-07-04 16:35 UTC. Not medical advice. Report errors via contact.